



Spruce Biosciences to Participate in May Investor Conferences

May 3, 2022

SAN FRANCISCO--(BUSINESS WIRE)--May 3, 2022-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.

- **RBC Capital Markets Global Healthcare Conference**

Date: May 17-18, 2022

Format: [Fireside chat](#) (May 17 at 10:00 a.m. ET) and 1x1 meetings

- **H.C. Wainwright Global Investment Conference**

Date: May 23-26, 2022

Format: [Company presentation](#) (May 25 at 4:00 p.m. ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the [Events](#) section of the company's investor relations website at <https://investors.sprucebiosciences.com>. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter [@Spruce_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220503005051/en/): <https://www.businesswire.com/news/home/20220503005051/en/>

Media Contact

Will Zasadny
Canale Communications
(619) 961-8848
will.zasadny@canalecomm.com
media@sprucebiosciences.com

Investors

Xuan Yang
Solebury Trout
(415) 971-9412
xyang@soleburytrout.com
investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.